阿托伐他汀对冠心病患者经皮冠状动脉介入术后血管内皮功能及血脂的影响

Effect of atorvastatin on vascular function and blood lipid in coronary heart disease patients with percutaneous coronary intervention

  • 摘要: 目的 探讨阿托伐他汀对冠心病患者经皮冠状动脉介入术(PCI)后血管内皮功能及血脂指标的影响。 方法 将90例冠心病行PCI患者随机分为治疗组和对照组,每组45例。对照组患者接受常规抗冠心病的药物治疗,治疗组在此基础上口服阿托伐他汀。比较2组治疗前后血脂指标(包括高密度脂蛋白、低密度脂蛋白、总胆固醇、甘油三酯)、血管内皮功能指标(血管内皮生长因子、一氧化氮)以及不良心血管事件发生率。 结果 治疗组的总胆固醇、甘油三酯、低密度脂蛋白水平显著低于对照组(P<0.05), 高密度脂蛋白水平显著高于对照组(P<0.05)。治疗后,治疗组的血管内皮生长因子、一氧化氮水平显著高于对照组(P<0.05)。治疗后,治疗组的心血管不良事件发生率为6.67%, 显著低于对照组的26.67%(P<0.05)。 结论 冠心病患者PCI术后接受阿托伐他汀治疗安全、有效,能够调节血脂水平,降低不良心血管事件的发生率。

     

    Abstract: Objective To explore the effect of atorvastatin on vascular endothelial function and blood lipid indexes in coronary heart disease patients with percutaneous coronary intervention(PCI). Methods A total of 90 patients with coronary heart disease after PCI were randomly divided into treatment group and control group, with 45 cases in each group. The control group was treated with conventional drugs for coronary heart disease, and the treatment group was treated with atorvastatin on the basis of the control group. Blood lipid indexes(including high-density lipoprotein, low-density lipoprotein, total cholesterol, triglyceride), vascular endothelial function indexes(vascular endothelial growth factor, nitric oxide)and incidence of adverse cardiovascular events were compared between the two groups before and after treatment. Results The levels of total cholesterol, triglyceride and low density lipoprotein in the treatment group were significantly lower than those in the control group(P<0.05), and the level of high-density lipoprotein was significantly higher than that of the control group(P<0.05). After treatment, the levels of vascular endothelial growth factor and nitric oxide in the treatment group were significantly higher than those in the control group(P<0.05). After treatment, the incidence of adverse cardiovascular events in the treatment group was 6.67%, which was significantly lower than 26.67% in the control group(P<0.05). Conclusion Atorvastatin is safe and effective in the treatment of patients with coronary heart disease after PCI, which can regulate levels of blood lipid indexes and reduce the incidence of adverse cardiovascular events.

     

/

返回文章
返回